Belgium has introduced a new digital reporting platform designed to strengthen safety monitoring in blood transfusion systems. The initiative was announced by the Federal Agency for Medicines and Health Products, which launched the online HemoVigilance application to streamline the reporting of serious adverse reactions and incidents related to blood donation and transfusion.
The new system aims to enhance regulatory oversight and improve the collection and evaluation of safety data associated with blood and blood components.
Purpose of the HemoVigilance System
Hemovigilance is a regulatory framework focused on monitoring, detecting, and analyzing adverse reactions and incidents that occur throughout the blood donation and transfusion process. Its objective is to ensure the continuous improvement of safety and quality in blood components and their clinical use.
The new HemoVigilance application allows healthcare professionals to report serious adverse reactions linked to blood donation or transfusion, as well as serious incidents that may affect the quality or safety of labile blood components. These reports enable regulators to systematically assess safety risks and implement corrective actions when necessary.
Digital Reporting to Replace Previous System
According to the Federal Agency for Medicines and Health Products, the online HemoVigilance platform officially replaces the previous reporting system starting in March 2026. All notifications related to serious adverse reactions or incidents must now be submitted through the new digital application.
The system allows designated contact persons within hospitals and blood transfusion establishments to submit reports quickly and efficiently through an electronic interface, improving reporting accuracy and regulatory response times.
Strengthening Safety Monitoring and Regulatory Oversight
The implementation of the HemoVigilance platform supports broader regulatory efforts to ensure the safety, quality, and availability of human biological materials, including blood products. By centralizing safety reports and enabling structured data analysis, regulators can more effectively detect potential safety issues and implement risk mitigation measures.
Modern vigilance systems increasingly rely on structured pharmacovigilance frameworks and safety monitoring procedures to ensure regulatory compliance and maintain robust safety surveillance programs. Organizations involved in safety monitoring activities often implement dedicated pharmacovigilance operational frameworks to support adverse event reporting, signal detection, and regulatory documentation processes.
https://www.baupharma.com/services-categories/pharmacovigilance/
Supporting Continuous Improvement in Blood Safety
Hemovigilance systems play a critical role in improving transfusion safety by systematically recording and evaluating adverse reactions and incidents associated with blood components. Data collected through these systems helps regulatory authorities identify trends, detect emerging safety risks, and implement preventive measures across healthcare institutions.
The launch of the HemoVigilance application represents another step toward strengthening regulatory vigilance and improving patient safety within Belgium’s healthcare system.
For more information: https://www.famhp.be/en/news/launch_of_the_new_online_application_hemovigilance
